Other
2022 Subject Index
Full Text
| Adverse drug reaction | 104 |
| Allergic contact dermatitis | 13 |
| Ankylosing spondylitis | 50 |
| Anogenital warts | 58 |
| Antimony compounds | 53 |
| Athlete | 86 |
| Basal cell carcinoma | 77 |
| Behçet’s disease | 50 |
| Biologics | 111 |
| Callus | 36 |
| Cancer | 94 |
| Case report | 50 |
| Certolizumab | 50 |
| Circumscribed morphea | 31 |
| Comparison | 46 |
| Corn | 36 |
| COVID-19 | 56, 62 |
| COVID-19 period | 46 |
| Cutaneous | 82 |
| Cutaneous leishmaniasis | 53 |
| Cutaneous malign melanom | 77 |
| Delayed | 13 |
| Demographics | 62 |
| Dermatology | 46 |
| Dermatology outpatients | 41 |
| Dermatoscopic examination | 86 |
| Diagnoses | 46 |
| Diagnosis | 33 |
| Disorder of keratinization | 24 |
| Disseminated | 24 |
| DLQI | 6 |
| Drug resistance | 27 |
| Early | 13 |
| Eczema | 6 |
| Erythroderma | 33 |
| Etiology | 33 |
| Folliculotropism | 65 |
| Hand-foot skin reaction | 104 |
| Hepatitis | 58 |
| Hidradenitis suppurativa | 21, 111 |
| HIV | 58, 82 |
| HOMA-IR | 36 |
| Human papilloma virus | 58 |
| Hydroxyurea | 101 |
| Inducible | 1 |
| Insulin Resistance | 36 |
| Interleukin (IL)-17A | 50 |
| Intralesional therapy | 53 |
| Kaposi sarcoma | 77 |
| Knowledge | 86 |
| Late reactions | 13 |
| Leishmania | 27 |
| Leukocytoclastic vasculitis | 69 |
| Lichen planus | 108 |
| Localized scleroderma | 31 |
| Maculopapular eruption | 56 |
| Melanoma | 94 |
| Melanonychia | 101 |
| Metabolic syndrome | 36 |
| Morphea | 31 |
| Morphea after waxing | 31 |
| Mucosal | 82 |
| Mycosis fungoides | 65 |
| Neutrophilic dermatoses | 69 |
| Neutrophilic dermatosis of the dorsal hands | 69 |
| Pandemic | 41, 62 |
| Patch test | 13 |
| Pathogenesis | 108 |
| Pediatrics | 21 |
| Phototherapy | 62 |
| Porokeratosis | 24 |
| Primary thrombocytosis | 101 |
| Psoriasiform | 53 |
| Psoriasis | 6 |
| Pyoderma gangrenosum | 69 |
| Reading time | 13 |
| SARS-CoV-2 | 41 |
| Secukinumab | 111 |
| Serological test | 58 |
| Sexually transmitted infections | 58 |
| Skin cancer | 86 |
| Sorafenib | 104 |
| Squamous cell carcinoma | 77 |
| STD | 82 |
| Sun | 86 |
| Sun exposure | 94 |
| Sunscreen | 94 |
| Sweet’s syndrome | 69 |
| Syphilis | 58 |
| Syringotropic | 65 |
| Treatment | 1, 27, 33, 41, 111 |
| Ulcerative colitis | 21 |
| Ultraviolet light | 94 |
| Unilateral | 56 |
| Urticaria | 1 |
| Vitiligo | 108 |